RE:RE:RE:RE:EU Legislative proposals aims to expedite new medicinesThe boundaries of the M&A playing field are expanding, propelled by interconnectedness and a standardization of international regulatory policies. As the large molecule biopharmaceutical industry expands , organizations must be prepared to explore opportunities beyond traditional small molecule drug treatment, and take a more wholistic approach that precision medicine intends to accomplish. This entails venturing into new strategic partnerships, and accessing promising assets and markets in emerging disease treatment sectors, including Orphan and Rare diseases. By adopting a mindset beyond conventional thinking and embracing new immuno-oncology treatment combinations, biomarkers, and predictive diagnostics, organizations can unlock new avenues for growth and expansion in the dynamic landscape of biopharmaceutical M&A, which ONCY's platform drug pelareorep is positioned to deliver on in multiple cancers, like the "orphan drug" space of metastatic pancreatic cancer (PDAC) and the"big disease" space of HER2- negative breast cancer.